Index

Note: Page numbers in italic refer to figures, those in bold to tables.

3 Ps of vasovagal syncope, 51
45 Trial, 27
ablation
energy forms for, 360
see also cardiac ablation
ACCOMPUSH trial, 244
ACE inhibitors, 389–391
Actinobacillus, 161
ACTION trial, 145
acute asthma attack
diagnosis of, 30
exacerbation features, 36
examination findings in, 36
key examination features, 35–36
acute coronary syndrome (ACS)
aetiology, 122
atypical symptoms, 125
clinical types, 122–124, 123
complications, 124–126
definition of, 119
development of, 120
diagnosis of, 14
diagnostic algorithm, 123
differentials, 126
entities in, 119
exacerbatory factors, 122
features associated with, 125
GRACE risk score, 130–131
key clinical trials, 136
key data, 122
key examination features, 18
key investigations, 127–131
management options, 131–135
normal ECG in, 127
pathophysiology, 121
presenting features, 124–126
risk scores, 130–131
signs of exacerbating conditions, 125
special tests, 129–130
TIMI score, 130
timing of PCI in, 130
underlying concepts, 119–122
acute myocardial infarction
criteria, 119
signs of complications, 18
acute pericarditis
aetiology, 246–247
treatment for, 251
vs. chest pain differentials, 247
differentials, 248
ECG, 249
key data, 246–247
key investigations, 249–250
management options, 250–251
pathophysiology, 246
presenting features, 247–248
risk factors, 248
acute pulmonary oedema
diagnosis of, 29
emergency management, 157
key examination features, 33–34
Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone trial, 190
Addison's disease, 98
adenosine, 367–368
adrenal insufficiency
diagnosis of, 97
key examination features, 101
AFASAK trial, 191
AFFIRM trial, 190
Agatson score (A score), 315–316
Aggreganabacter, 151
alcohol, 52, 55
aldosterone, 389–390, 396
allergies, cross-reactions,
features of, 204
associated murmurs, 208
auscultatory findings in, 209
diagnosis of, 77–78
echocardiographic image
characteristics of, 209
DeBakey classification, 15
diagnosis of, 14–15, 74–75
features of, 204
and hypertension (HTN), 233
diagnosis of, 14–15, 74–75
features of, 204
see also aortic regurgitation (AR)
aortic dissection
DeBakey classification, 15
diagnosis of, 14–15, 74–75
features of, 204
and hypertension (HTN), 233
diagnosis of, 14–15, 74–75
features of, 204
TOE image of, 295
TOE interpretation, 296
see also coarctation of the aorta (CoA)
aortic regurgitation (AR)
aetiology, 208
associated murmurs, 208
auscultatory findings in, 209
diagnosis of, 77–78
differentials, 209
Doppler image, 78
ECG findings in, 210
minimally significant in,
key examination features, 211
murmur characteristics of, 209
pathophysiology, 207–208
presenting features, 208–209
aortic sclerosis, 205
diagnosis of, 75–76
key examination features, 82
aortic stenosis (AS)
aetiology, 204
auscultatory findings in, 205
diagnosis of, 76

418 Index

aortic stenosis (AS) (Continued)
differentials, 205
ECG findings in, 206
key data, 204
key examination features, 82–83
key investigations, 206–207
management options, 207
mechanisms of shortness of breath, 203
murmur characteristics, 205
pathophysiology, 203–204
presenting features, 204–205
prevalence, 204
side effects of, 204
aortic valve (AV) calcified, 76
fluoroscopy images of valvuloplasty, 349
vegetation on, 88, 160
see also transaortic valve implantation (TAVI)
aortogram, fluoroscopic imaging, 324
apex beat, 6
arrhythmias, 221
to be aware of, 189–190
cardiac catheterization, 325
clinical types, 172–173
definition of, 172
diagnosis of, 49
examination for, 3
key clinical trials, 190–191
key examination features, 53
termination of, 378
underlying concepts, 172
arrhythmogenic (right ventricular) cardiomyopathy, 231
arterial blood gas (ABG), reading/sampling of, 41
ascites, causes of, 109
ASCOT trial, 243
Aspergillus, 161
aspirin, 170, 204
Assignment of atrioventricular junction ablation trial, 364
asthma
features of exacerbation, 36
see also acute asthma attack
tetanus, 243, 378–379
atherosclerosis, and hypertension (HTN), 233
atorvastatin, 414–415
atria
TOE interpretation, 296
TTE interpretation, 302
atrial ectopics
diagnosis of, 65
key examination features, 67
atrial fibrillation (AF), 63, 221
aetiology, 173
bleeding risk assessment, 179
clinical types, 174
definition of, 173
diagnosis of, 65–66
differentials, 175
ECG, 173, 289
indications for PVI in, 361
key data, 173–174
key examination features, 67–68
key history features, 65–66
key investigations, 175–176
management options, 176–179
oral anticoagulants, 179
pathophysiology, 174
presenting features, 175
and thromboemboli, 174
thrombotic risk assessment, 179
trigger factors, 177
atrial flutter, 179
eaetiology, 180
clinical types, 180–181
definition of, 180
differentials, 181
ECG, 180
key data, 180
key investigations, 181
management options, 181
pathophysiology, 180
presenting features, 181
atrial myxoma
diagnosis of, 52–53
key examination features, 56
atrial septal defect (ASD), 262
eaetiology, 262–263
anatomy, 262
differentials, 264
Doppler image, 80
ECG findings in, 265
indications for closure, 266
key data, 262–263
key investigations, 264–265
management options, 265–266
maternal risk factors, 263
pathophysiology, 262
presenting features, 263–264
atrioventricular block, pacemaker selection, 333
atrioventricular nodal re-entrant tachycardia (AVNRT), 182
atrioventricular re-entrant tachycardia (AVRT), 182
atropine, 59, 335, 373–374
auscultation
in aortic regurgitation (AR), 209
in aortic stenosis (AS), 205
in atrial septal defect (ASD), 263
in coarctation of the aorta (CoA), 271
locations for cardiac valves, 194
in mitral regurgitation (MR), 196
in mitral stenosis (MS), 209
in ventricular septal defect (VSD), 267
Austin Flint murmur, 201
autoregulation, 233
back, examination findings, 8
bacterial pericarditis
causes of, 246
mortality, 247
balloon aortic valvuloplasty (BAV), procedural outline, 348
Bartonella, 161
bed, examination from end of, 4
bendroflumethiazide, 243, 394–396, 396
benzothiazepines, 380
beta-adrenoceptors, sites of, 375
beta-blockers, 155, 375–379
cardioselective see cardioselective beta-blockers
effect on smooth muscle, 375
and heart failure (HF), 376
and hypertension, 375
key clinical trials, 379
and liver, 376
myocardial effect, 375
non-selective see non-selective beta-blockers
dipropyl, 158, 377–379
bleeding risk in AF, 179
post PCI, 345
blood flow, MRI quantification, 309
blood pressure goals in hypertension (HTN), 241
measurement of, 240
Boerhaave's rupture
diagnosis of, 16
key examination features, 19
bradyarrhythmias, 63
key examination features, 67
key history features, 64–65
bradykinin, 385, 396–398
brain natriuretic peptide (BNP), causes of raised, 151
breath, shortness of see shortness of breath
BREATHE-5 trial, 275
bronchospasm, symptoms of, 298
Brucella, 161, 166
Brugia malayi, 109
bunometamide, 393–394
burns, fluid requirements, 94
calcium scoring, 315–316
calcium-channel blockers, 380–384
cardiac selective see cardiac selective calcium-channel blockers
Candida, 161
cannulation, in TOE, 296
captopril, 107, 389–391
carbamazepine, 381
Cardiac ablation
accessory pathway, 360
AV nodal (slow pathway), 360
AV nodalHis bundle, 359
cavo-tricuspid isthmus, 360
complications, 362–363
definition of, 359
ECG, 361
indications, 361
key clinical trials, 363–364
peri-procedural management, 362
procedural outline, 359–361
pulmonary vein obliteration, 363
RVOT, 360
cardiac anatomy, 122
and ECG leads, 339
MRI interpretation, 308
cardiac arrhythmia, see arrhythmias

cardiac axis
causes of left deviation, 284
causes of right deviation, 285
of ventricular depolarization, 284

cardiac biomarkers, 121
levels of, 121

cardiac catheterization

cardiac suite, 321
common catheters, 320
complications, 325
definition of, 320
discharge instructions, 324
entry site bleeding post PCI, 345
four main subtypes of, 323
image of balloon, 349
indications, 322–323
interpretation, 324–325
left vs. right heart, 322
peri-procedural management, 323–324
procedural outline, 320–322
sample catheters, 322
transient arrhythmia, 325
cardiac chest pain
typical features, 125
see also chest pain
cardiac CT
3D anatomical views, 317
calcium scoring, 315–316
complications, 317
testrindication, 314
and coronary artery bypass graft (CABG), 314
definition of, 313
indications, 314
interpretation, 315–317
key clinical trials, 318
multi-detector (MDCT), 313–314
non-cardiac findings, 315
peri-procedural management, 314–315
procedural outline, 313
and stent assessment, 314
cardiac failure, see congestive cardiac failure (CCF)
cardiac glycoside, 371
cardiac MRI
complications, 310
contraindications, 308
definition of, 306
delayed gadolinium
hyper-enhancement, 310
in dilated cardiomyopathy (DCM), 226
and foreign bodies, 308
indications, 307
interpretation, 308–310
key clinical trials, 311
normal, 309
peri-procedural management, 307–308
procedural outline, 306–307
typical scanner, 306
cardiac murmurs
calling a senior, 89–90
characteristics of, 73
classification of, 72–73
definition of, 72
differentials, 73–74
from metallic heart valves, 85
key clinical trials, 90–91
key examination features, 80–86
key history features, 74–80
key investigations, 86–89
potential underlying causes, 73
work-up of presenting patient, 89
cardiac outflow, causes of obstruction, 48
cardiac reynchronisation therapy (CRT)
in dilated cardiomyopathy (DCM), 227
in heart failure (HT), 155
indications for, 332
cardiac risk factors, 14
cardiac selective calcium-channel blockers, 380–382
acting on smooth muscle, 382–383
clinical trials, 384
cardiac surgery, scars from, 86
cardiac valves, auscultation locations for, 194
Cardiobacterium hominis, 161
cardiogenic shock
diagnosis of, 96
key examination features, 100
cardiomyopathy, 231
clinical types, 214–216
presenting features, 216
considerations in patients with, 216
definition of, 214
differences between types, 215
presenting features, 216
underlying concepts, 214
see also dilated cardiomyopathy;
hypertrophic cardiomyopathy;
restrictive cardiomyopathy
cardioselective beta-blockers, 377–378
cardiovascular risk calculators, 240
CARE-HF trial, 337
carotid massage, performance of, 59
carotid sinus hypersensitivity
diagnosis of, 52
key examination features, 55
CAST I trial, 374
catheterization, see cardiac catheterization
catheters
common, 320
sample cardiac, 322
CE-MARC trial, 311
cerebrovascular events
diagnosis of, 51
key examination features, 54
CHA2DS2-VASc score, 179
chest pain
vs. acute pericarditis differentials, 247
bedside investigations, 22–23
calling a senior, 25–26
CXR findings, 24
definition of, 13
diagnostic algorithm, 13
differentials, 13–14
ECG findings, 23
key clinical trials, 26–27
key examination features, 18–21
key history features, 14–18
key investigations, 21–25
musculoskeletal cause of, 17, 21
psychiatric cause of, 18, 21
chest X-ray (CXR)
in chest pain, 24
in dilated cardiomyopathy (DCM), 225
features of HF (ABCDE), 152
Kerley B lines, 153
of lobar pneumonia, 44
of pericardial effusion, 257
of permanent pacemaker, 336
of pleural effusion, 43
of pneumonia, 44
of pulmonary oedema, 152
chronic obstructive pulmonary disease (COPD)
diagnosis of, 32
infective exacerbation of, 31
key examination features, 38–39
CIBIS II trial, 158, 379
circular artery, stenosis of, 343–344
classification, of heart failure (HF), 149
clopidogrel, 133, 135, 136, 340, 342, 410–412
clotting factors, half-lives of, 404
clubbing
infective endocarditis (IE), 164
stages of, 4
coagulation tests, 407
coracoid of the aorta (CoA)
atiology, 270
anatomy, 270
auscultatory findings in, 271
causes of death, 270
clinical types, 271
definition of, 270
differentials, 271
indications for invasive intervention, 273
key data, 270
key investigations, 271–272
management options, 272–273
pathophysiology, 270
presenting features, 271
collapse, arrhythmic causes of, 48
COMMIT trial, 136
common conditions, examination for, 3
comparison of balloon-expandable stent
implantation with balloon angioplasty, A, 346
complete heart block, 56
diagnosis of, 64–65
key examination features, 67
computed tomography (CT)
coronary angiogram, 314
multi-detector (MDCT), 313–314
pericardial effusion, 255
pulmonary angiogram, 58
see also cardiac CT
CONFIRM trial, 318
congenital heart disease
acyanotic/cyanotic, 261
definition of, 261
diagnosis of, 79
complications, 292
chronic heart failure (CHF), 150
in hypertrophic cardiomyopathy (HCM), 219
signs of IE, 164
signs of, 165
subcutaneous emphysema, 162
Enterococcus, 161, 162
EPHESUS trial, 136
epileptic seizures
diagnosis of, 50
key examination features, 54
eplerenone, 136, 158, 396–397
European Society of Cardiology (ESC) grades of hypertension (HTN), 240
rhythm control, 177–178
extrasystoles, 63
key examination features, 67
key history features, 65
exudative pericardial effusion, definition of, 258
eyes, examination findings, 5
Fallot’s tetralogy, 273–274
FAME-2 Trial, 26–27
felodipine, 382–383
fibrillation
definition of, 109
diagnosis of, 109
key examination features, 112–113
findings, presentation of, 9
flexicainide, 177, 184, 370–371, 374, 394
flow murmur
diagnosis of, 79
key examination features, 84
fluoroscopic imaging
theorgram, 324
catheter balloon, 349
guide wire, 349
left ventriculogram, 322
fondaparinux, 133, 342, 400, 402–403, 407
Framingham criteria, 111
Framingham Heart Study, 26
Frank–Starling curve, 147
furosemide, 46, 157, 372, 388, 393, 394
gastro-oesophageal reflux disease (GORD)
diagnosis of, 17
key examination features, 21
Gerbode defect, 267
GSSI-3 trial, 388
Global Registry of Acute Coronary Events (GRACE), 130
risk score, 131
glycerol trinitrate (GTN), 4, 125, 145, 157, 207, 247, 320, 385, 387–388, 400
patches, 387
spray, 16, 133, 141, 144, 386
sublingual, 16, 313
GRACE score, and PCI failure risk, 341
group IC anti-arrhythmic, 370
group III anti-arrhythmic, 368
Haemophilius, 161
haemorrhage, sites of, 94
haemorrhagic shock, classes of, 99
hand examination findings, 4
signs of IE, 164
HAS-BLED score, in AF, 179
heart chambers and valves, 193
left/right catheterization interpretation, 325
normal conduction in, 172
heart block
case see complete heart block
first-degree, 165
heart failure (HF), see congestive cardiac failure (CCF)
heart sound, 7–8
heparin, 399–400
low molecular weight see low molecular weight heparins (LMWHs)
reversal of, 400
heparin-induced thrombocytopenia (HIT), 400
herpes zoster, and chest pain, 18, 21
hypertension (HTN)
accelerated, 236
arterial, 234–235
aims of investigations, 238
and aortic dissection, 233
and atherosclerosis, 233
and beta-blockers, 375
and blood pressure goals in, 241
chronic, 236–237
clinical types, 235–236
and CV risk, 240
definition of, 232
diagnosis of, 232
differential, 238
drugs causing, 235
endocrine causes of, 235
ESC grades of, 240
and hypertensive encephalopathy, 234
and hypertensive nephropathy, 233–234
and hypertensive retinopathy, 234
imaging modalities, 238–239
and intracerebral haemorrhage, 234
and ischaemic stroke, 234
and ischaemic stroke, 234
key clinical trials, 343–344
key data, 234–235
key investigations, 238–239
and left ventricular pressure overload, 233
lipid-lowering therapy, 242
major complications of, 233–234
malignant, 236
Management options, 239–243, 242
NCE categorization of, 240
pathophysiology, 232–233
presenting features, 236–237
primary vs. secondary, 235
secondary causes of, 237
treatment options, 241–243
undertaking concepts, 232–234
when to treat, 240–241
hypertensive emergency, 235–236
management of, 243
most common, 236
symptoms of, 236
hypertensive encephalopathy, and hypertension (HTN), 234
hypertensive end-organ damage, 237
hypertensive nephropathy, and hypertension (HTN), 234
hypertensive retinopathy and hypertension (HTN), 234
stages of, 234
hypertensive urgency, 236
hypertrophic cardiomyopathy (HCM) aetiology, 216
definition of, 216
differentials, 218
ECG changes in, 219
echocardiographic findings in, 220
factors associated with worse prognosis, 217
ICD indications in, 221
key data, 216–217
key examination features, 83
key investigations, 218–220
management options, 221
pathophysiology, 217
presenting features, 217–218
sarcomeric protein mutations associated with, 216
sinus rhythm in, 219
trans-thoracic echocardiogram (TTE), 220
hypertrophic obstructive cardiomyopathy (HOCM), 211
hypoglycaemia diagnosis of, 51
key examination features, 54
hypoperfusion, 119
hypovolaemic shock diagnosis of, 93
key examination features, 98–99
immunology, causing acute pericarditis, 247
implantable cardiac defibrillators, 37
definition of, 329
indications, 335
implantable cardioverter-defibrillators (ICDs), 155
in dilated cardiomyopathy (DCM), 227
in hypertrophic cardiomyopathy (HCM), 221
indapamide, 395–396
infarction, ECG, 290
infection diagnosis of, 108
key examination features, 111
resulting in constrictive pericarditis, 252
infective endocarditis (IE) aetiology, 161
antiplatelets/anticoagulation in, 169
aortic valve vegetation, 160
bottom line, 163
clinical types, 162–163
clubbing, 164
complications of, 165
culture-negative endocarditis, 161
diagnosis of, 160
diagnosis of, 75, 168
differentials, 165–166
Duke’s criteria for diagnosis, 168
empirical antibiotic treatment, 169
examination for, 3
hard signs of, 164
key clinical trials, 170
key data, 161–162
key examination features, 82
key investigations, 166–168
less common features of, 163
management options, 168–170
microbiology, 161
peripheral stigmata, 82
poor outcome predictors, 162
presenting features, 163–165
surgery in, 170
underlying concepts, 160–161
vegetation on aortic valve, 212
infarction, ECG, 252
implantable cardioverter-defibrillators, 331
implantable cardiac defibrillators,
immunology, causing acute pericarditis, 247
hypertensive end-organ damage, 237
hypertensive nephropathy, and hypertension (HTN), 234
hypertensive retinopathy and hypertension (HTN), 234
stages of, 234
hypertensive urgency, 236
hypertrophic cardiomyopathy (HCM) aetiology, 216
definition of, 216
differentials, 218
ECG changes in, 219
echocardiographic findings in, 220
factors associated with worse prognosis, 217
ICD indications in, 221
key data, 216–217
key examination features, 83
key investigations, 218–220
management options, 221
pathophysiology, 217
presenting features, 217–218
sarcomeric protein mutations associated with, 216
sinus rhythm in, 219
trans-thoracic echocardiogram (TTE), 220
hypertrophic obstructive cardiomyopathy (HOCM), 211
hypoglycaemia diagnosis of, 51
key examination features, 54
hypoperfusion, 119
hypovolaemic shock diagnosis of, 93
key examination features, 98–99
immunology, causing acute pericarditis, 247
implantable cardiac defibrillators, 37
definition of, 329
indications, 335
implantable cardioverter-defibrillators (ICDs), 155
in dilated cardiomyopathy (DCM), 227
in hypertrophic cardiomyopathy (HCM), 221
indapamide, 395–396
infarction, ECG, 290
infection diagnosis of, 108
key examination features, 111
resulting in constrictive pericarditis, 252
infective endocarditis (IE) aetiology, 161
antiplatelets/anticoagulation in, 169
aortic valve vegetation, 160
bottom line, 163
clinical types, 162–163
clubbing, 164
complications of, 165
culture-negative endocarditis, 161
diagnosis of, 160
diagnosis of, 75, 168
differentials, 165–166
Duke’s criteria for diagnosis, 168
empirical antibiotic treatment, 169
examination for, 3
hard signs of, 164
key clinical trials, 170
key data, 161–162
key examination features, 82
key investigations, 166–168
less common features of, 163
management options, 168–170
microbiology, 161
peripheral stigmata, 82
poor outcome predictors, 162
presenting features, 163–165
surgery in, 170
underlying concepts, 160–161
vegetation on aortic valve, 212
infarction, ECG, 252
implantable cardioverter-defibrillators, 331
implantable cardiac defibrillators,
immunology, causing acute pericarditis, 247
Index 423

key data, 199–200
key examination features, 84
key investigations, 201–202
management options, 203
murmur characteristics, 201
pathophysiology, 199–200
precipitants of progression, 200
presenting features, 200
mitral valve
diagnosis of prolapse, 77
key examination features of prolapse, 83
vegetation on, 167
mouth, examination findings, 5
MR-IMPACT II trial, 311
multi-detector row computed tomography (MDCT), coronary angiogram, 314
multifocal atrial tachycardia, 189
ECG, 190
murmurs
Austin Flint, 201
to be aware of, 211–212
characteristics of aortic regurgitation (AR), 209
characteristics of aortic stenosis (AS), 205
characteristics of mitral regurgitation (MR), 196
characteristics of mitral stenosis (MS), 201
innocent, 212
Levine Scale of intensity, 194
myocardial infarction (MI)
definition of types, 121
diagnosis of, 23, 75
ECG changes in, 22
indicators in CPI, 341
key examination features, 81–82
long-term treatment, 135
pathological features of, 124
vs. unstable angina, 123
myocardial ischaemia, 119
myocardial viability, MRI assessment, 309
nails, examination findings, 4
NASPE/BPEG pacemaker coding, 331
National Institute for Health and Care Excellence (NICE), categorization of hypertension (HTN), 240
neck, examination findings, 5
nephrogenic systemic fibrosis, 310
nephropathy, contrast-induced, 345
nephrotic syndrome
causes of, 108
key examination features, 110
neurogenic shock
diagnosis of, 97
key examination features, 101
nicotine, stains from, 139
nifedipine, 145, 266, 269, 380,
382–383
dosing of, 383
particulars of, 382
nitrate tolerance, 387
nitrate withdrawal, 386
nitrates, 385–388
drug–drug interactions, 385
oral see oral nitrates
n mechanism of action, 385
used as an infusion see glyceryl trinitrate (GTN); infusion nitrates
non-atherosclerotic myocardial infarction, 126
non-compaction cardiomyopathy, 231
non-selective beta-blockers, 376–377
non-cardiac indications, 376
non-ST-elevation acute coronary syndrome (NSTE-ACS), early invasive strategy, 135
non-ST-elevation myocardial infarction (NSTEMI), 126
ECG changes in, 127
management of, 135
novel antplatelets, 411–413
nutrients, signs of deficiency, 112
OASIS 5 trial, 407
OASIS 6 trial, 407
obstructive cardiomyopathy, key examination features, 83
obstructive shock
causes of, 96
diagnosis of, 96–97
key examination features, 100
and pneumothorax, 97
oesophagus
calling a senior, 115–116
definition of, 106
diagnostic algorithm, 106
differentials, 106–107
key clinical trials, 116
key examination features, 110–113
key history features, 107–110
key investigations, 113–115
pathophysiology of, 106
pulmonary CXR, 152–153
oesophageal perforation, features of, 363
oesophageal rupture, 16
key examination features, 19
oesophageal spasm
diagnosis of, 17
key examination features, 21
Onchocerca volvulus, 109
oral anticoagulants, 179, 406–407
reversal, 407
use of coagulation tests with, 407
oral nitrates, 385–387
outflow obstruction
diagnosis of, 49
key examination features, 53
P-waves, 285
pacemakers
and bacterial infection, 336
biventricular, 330
coding, 331
complications, 336
components of check, 332
definition of, 329
dual-chamber, 330
indicators, 332–335

pacemakers (Continued)
key clinical trials, 336–337
NASPE/BPEG coding, 331
outline of devices, 329–330
peri-procedural management,
335–336
permanent, 329–330, 332, 336
percutaneous coronary intervention
peak flow measurement, performance
PC trial, 275
patent ductus arteriosus (PDA), 273
PARTNER trial, 212, 357
Parkland formula, 94
palpitations
calling a senior, 69–70
definition of, 62
diagnostic algorithm, 62
differentials, 62–63
exogenous substances associated
with, 63
key examination features, 66–68
key history features, 63–66
key investigations, 68–69
medical conditions associated with,
63
Parkland formula, 94
PARTNER trial, 212, 357
patent ductus arteriosus (PDA), 273
PC trial, 275
peak flow measurement, performance
by patient, 40
percutaneous coronary intervention
(PCI)
in ACS, 130
antiplatelet agents used in, 340
basic principles, 338–339
complications, 344–345
contraindications, 341
definition of, 338
and elective angiography, 340–341
and GRACE score, 341
indications, 340–341
interpretation, 343–344
key clinical trials, 346–347
multi-vessel disease in, 134
patient advice, 342
patients with renal disease, 342
peri-procedural management,
341–342
primary emergency, 340
procedural outline, 340
and STEMI, 345–346
and stenotic lesions, 341
urgent, 340
perfusion, examination for poor, 3
pericardial disease
anatomy, 245
clinical types, 245–246
definition of, 245
diagnosis of, 300
morphological classification, 245
pathophysiology, 245
temporal classification, 246
underlying concepts, 245
pericardial effusion
aetiology, 255
common causes, 254–255
CT scan, 255
CXR of, 257
defining an exudative, 258
differentials, 256
effect of, 256
key clinical trials, 259
key data, 255
key investigations, 256–259
management options, 259
pathophysiology, 254–255
presenting features, 255–256
TTE of, 258
pericardial fluid
analysis of, 258
analytical tests for, 259
pericardial friction rub, features of, 248
pericardectomy
complications, 254
standard approach options, 254
pericardiocentesis, contraindications for,
259
pericarditis
diagnosis of, 16
key examination features, 20
in renal failure, 248
resulting from transmural MI, 248
see also acute pericarditis; bacterial
pericarditis, constrictive
pericarditis; pericardial effusion
pericardium
TOE interpretation, 297
TTE interpretation, 302
peripheries, clinical examination of, 3–6
phenylalkylamines, 380
phenytoin, 369, 381, 404
phenylpropionate, 380
peripheral
clinical examination of, 3–6
pleural effusion
Diagnosis of, 29–30
key examination features, 35
and obstructive shock, 97
Pisottele's law, 232
postural hypotension
diagnosis of, 52
key examination features, 55
potassium-sparing diuretics, 396–397
PR interval, 286
praecordium
auscultation of, 7
clinical examination of, 6–8
inspection features of, 6
palpation features of, 6
prasugrel, 133, 135, 340, 342, 411–413
pravastatin, 414–415
presentation examples, shortness of
breath and leg swelling, 9
PREVENT trial, 384
Prevention of Syncope Trial (POST), 60
prior myocardial infarction, criteria, 119
procedural guidance, 301
ProCOSS trial, 104
prophylaxis, 169
propranolol, 376, 378
prophylactic
heart valve
diagnosis of, 79
key examination features, 85
murmur, 211
prosthetic valve dysfunction
diagnosis of, 74
key examination features, 80–81
pseudo-seizures, 53
pulmonary angiogram, computed
tomography (CT), 58
pulmonary embolism (PE)
diagnosis of, 15, 29, 49–50
key examination features, 19, 34,
53–54
Wells’ score for, 50
pulmonary fibrosis
diagnosis of, 32–33
key examination features, 39–40
pulmonary function test results, 41
pulmonary hypertension, causes of,
149
pulmonary oedema, CXRs of, 152–153
pulmonary valve disease, 211
pulmonary vein isolation (PVI), 359, 361
ablation, 178, 361
pulmonary vein obliteration, after PVI
ablation, 363
pulse character, central, 6
puncture-site bleeding, management of,
351
pulmonary embolism, 255
pyrexia of unknown origin (PUO), rare
causes of, 166
Q-waves, 282
ORs complex, 286
QT interval, calculation of, 283
radio-calcium delay, causes of, 19
RALES trial, 116, 398
ramipril, 389, 390–391
Randomized trial of high-dose
isosorbide dinitrate plus low-dose
furosemide, 388
rate control, 177
RAVEL study, 346
Re-interventions after percutaneous
mitral commissurotomy during
long-term follow-up trial, 212
RE-LY trial, 408
reinforcement manoeuvres, 7
renal disease, in PCI patients, 342
renal failure, resulting in pericarditis,
248
renin, 147, 375, 389–390, 395, 398
restrictive cardiomyopathy (RCM)
aetiology, 227
definition of, 227
differentials, 229
ECG findings in, 229
echocardiographic findings, 230
factors associated with poor prognosis, 228
key data, 227–228
key investigations, 229–230
management options, 230
pathophysiology, 228
presenting features, 228–229
revascularization, angiographic indications for, 343
REVEAL(TM) device, for palpitations/syncope, 69
rhythm, in ECG, 284
right bundle branch block, ECG, 291
right coronary artery, 338
anatomy, 339
origins of, 339
structures supplied by, 338
right dominance, 339
right ventricle
TOE interpretation, 296
TEE interpretation, 302
right ventricle outflow tract (RVOT), 360
right ventricular function, MRI quantification, 308
risk assessment/stratification, 301
rivaroxaban, 396–407
ROMICAT trial, 318
safety first approach to findings, 9
sarcomeric protein mutations, associated with HCM, 216
scars, from cardiac surgery, 86
Second Vasovagal Pacemaker Study (VPS II), 60
segments in ECG, 282–283, 285–287
see also ST segment
seniors, calling of in cardiac murmurs, 89–90
in chest pain, 25–26
in loss of consciousness, 59–60
in oedema, 115–116
in palpitations, 69–70
in shock, 103
in shortness of breath, 45–46
sepsis six, 103
septic shock
diagnosis of, 94–95
key examination features, 99
and pneumocystis pneumonia (PCP), 95
shock
ABCD: monitoring, examination and action, 98
calling a senior, 103
classes of haemorrhage, 99
definition of, 92
diagnostic algorithm, 92
differentials, 93
key clinical trials, 103–104
key examination features, 98–101
ShOCK trial, 104
shortness of breath calling a senior, 45–46
definition of, 28
diagnostic algorithm, 28
differentials, 28–29
key examination features, 33–40
key history features, 29–33
key investigations, 40–45
mechanisms in aortic stenosis (AS), 203
respiratory findings in diagnoses, 40
signs, eponymous, 10
sildenafil, 386
simvastatin, 27, 404, 414–415
sinus arrhythmia, 288
sinus bradycardia
diagnosis of, 64
diagnostic algorithm, 64
differentials, 67
subtypes of, 332
sinus node dysfunction, pacemaker selection, 334
sinus rhythm, 63, 287
definition of, 288
diagnosis of, 66
key examination features, 68
key history features, 66
sinus tachycardia, 63
diagnosis of, 66
key examination features, 68
key history features, 66
slips, 52, 55
smooth muscle action of calcium-channel blockers on, 382–383
effect of beta-blockers on, 375
SOVD-treatment trial, 158
ST elevation, causes of, 286
STElevation myocardial infarction (STEMI), 345–346
ECG changes in, 127
management of, 134
ST segment, 286
stable angina
aetiology, 138–139
classification of, 140
clinical types, 140
daily diet, 144
diagnosis of, 138
diagnosis of, 16
differentials, 141
ECG findings in, 142
ischaemic changes, 142
key clinical trials, 145
key data, 138–140
key examination features, 20
key investigations, 142–144
management options, 144–145
medications, 145
pain in, 141
presenting features, 140–141
risk factors, 138–139
underlying concepts, 138
Stanford classification, 15
Staphylococcus aureus, 161, 162, 336
statins, 74, 144, 242, 413–415
stenosis, of proximal left circumflex artery, 343–344
stenotic lesions, and percutaneous coronary intervention (PCI), 341
stenosis assessment, CT angiography in, 314
stents, drugs eluted from, 342
Stokes Adams attacks, 49, 56
Streptococcus bovis, 161, 162
equinus, 161
structural cardiac disease, diagnosis/surveillance, 300
subcutaneous emphysema, causes of, 20
supraventricular arrhythmias
presenting features, 182
types of, 182
supraventricular tachycardias (SVTs), 181
aetiology, 181
clinical types, 182
definition of, 181
diagnosis of, 63–64
differentials, 182
ECG, 289
key data, 181–182
key examination features, 66
key investigations, 183
managing features, 184
presenting features, 182
surgery, infective endocarditis (IE), 170
coronal intervention (PCI), 341
surgical drainage, 259
Surgical treatment for secundum ASD
symptoms, eponymous, 10
syringe, see loss of consciousness syndromes
associated with HCM, 216
thyrotoxicosis, 20
T-wave, causes of inversion, 287
tachyarrhythmias, 62
key examination features, 66–67
key history features, 63–64
tachycardia
supraventricular see supraventricular tachycardia
ventricular see ventricular tachycardia
Takotsubo cardiomyopathy, 231
temporary pacing wire, 331
Tension pneumothorax
diagnosis of, 15
key examination features, 19
theophylline, 367, 383
ThermoCool trial, 363
thiazides, 394–396
thrombocytopenia, heparin-induced (HIT), 400
thromboplastin, in atrial fibrillation (AF), 174
thrombolysis, and PCI, 345–346
Thrombolyis in Myocardial Infarction (TIMI) Study Group, 130

thrombotic risk assessment in AF, 179

transoesophageal echocardiogram (TOE)

valvuloplasty

ventricular septal defect (VSD), 266

ventricular rate, calculation of, 284

ventricular tachycardia (VT)
aetiology, 185

clinical types, 187
definition of, 185
differentials, 187

Doppler image, 80

indications for closure, 270

key data, 267

key investigations, 268–269

management options, 269–270

maternal risk factors for, 267

pathophysiology, 266

presenting features, 267–268

ventricular size/function, 147

ventricular tachyarrhythmias, high risk conditions, 335

ventricular tachycardia (VT)
aetiology, 185

clinical types, 187
definition of, 185
differentials, 187

ECG, 184, 291
electrolyte disturbances predisposing to, 185

key data, 184–186

key examination features, 66–67

key investigations, 187–188

management options, 189

pathophysiology, 186–187

presenting features, 187

terms in, 185

ventricular tachycardias, 360

ventriculogram, fluoroscopic imaging, 323

verapamil, 320, 369–370, 377, 380, 381–382, 413, 415

viruses, causing acute pericarditis, 246

ward-round-based approach to findings, 9

warfarin, 4, 128, 176, 179, 191, 296, 323, 342, 356, 362, 403–408

agents increasing/decreasing effect of, 404

international normalized ratio (INR) targets, 405

reversal of, 405

waves in ECG, 281–282, 285–287

non-pathological, 281

pathological, 282

see also P-waves; Q-waves

Wells' score for DVT, 50

for PE, 50

whispered pectoriloquy, 37

Wilson’s central terminal, 280

wrist, examination findings, 5

Wuchereria bancrofti, 109